Myelodysplastic Syndrome (MDS) Cell Models for Research

Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by dysplasia, ineffective hematopoiesis, and increased risk of acute myeloid leukemia (AML). The global incidence is approximately 4-5 per 100,000 person-years, rising to over 30 per 100,000 in individuals over 70 years (WHO, 2020). The median age at diagnosis is 71 years. Risk factors include advanced age, prior chemotherapy or radiation exposure, and genetic predisposition. The 5-year survival rate varies widely by risk category, ranging from less than 10% for high-risk MDS to over 70% for low-risk cases (NCI SEER). MDS is a significant clinical challenge due to its complex biology and limited therapeutic options.

MDS is an ideal model for studying clonal evolution, epigenetic dysregulation, and the interplay between genetic mutations and the bone marrow microenvironment. Public datasets such as TCGA and COSMIC provide extensive genomic and transcriptomic data, enabling researchers to identify recurrent mutations and pathways. Open questions include the mechanisms of disease progression, the role of splicing factor mutations, and the development of targeted therapies. Gene-edited cell models are crucial for functional validation of these mutations and for drug screening.

MDS pathogenesis involves several key pathways:

• • RNA splicing: Mutations in SF3B1, SRSF2, U2AF1, and ZRSR2 lead to aberrant splicing, affecting genes involved in hematopoiesis.
• • Epigenetic regulation: Mutations in TET2, DNMT3A, IDH1/2, and ASXL1 disrupt DNA methylation and histone modifications, leading to altered gene expression.
• • DNA damage response: Mutations in TP53 and ATM impair DNA repair, promoting genomic instability.
• • Signal transduction: Mutations in RAS family genes (NRAS, KRAS) and JAK2 activate proliferative pathways.

These pathways often cooperate to drive clonal expansion and differentiation block.

Data from TCGA and COSMIC.

Key signaling networks deregulated in MDS include:

• • JAK-STAT pathway: Mutations in JAK2, STAT3, and STAT5 lead to aberrant cytokine signaling and proliferation.
• • PI3K/AKT/mTOR pathway: Activated by RAS mutations, promoting cell survival and growth.
• • MAPK pathway: RAS/RAF/MEK/ERK cascade is constitutively activated, driving proliferation.
• • NF-κB pathway: Chronic inflammation activates NF-κB, contributing to apoptosis resistance.
• • Wnt/β-catenin pathway: Dysregulated in some MDS subtypes, affecting stem cell self-renewal.

These networks offer potential therapeutic targets.

Organoid models, such as bone marrow organoids, are emerging as more physiologically relevant systems, allowing study of the microenvironment and drug responses.

Animal models for MDS include:

• • Patient-derived xenografts (PDX): Immunodeficient mice engrafted with patient MDS cells, preserving genetic heterogeneity.
• • Genetically engineered mouse models (GEMM): Knock-in or knockout of MDS-associated genes (e.g., Tet2, Sf3b1) to recapitulate disease features.
• • Induced models: Treatment with chemical mutagens or irradiation to induce MDS-like disease.

These models are valuable for studying disease mechanisms and testing therapies.

Gene-edited cell models, particularly CRISPR-based isogenic lines, are essential for functional studies. These models are created by introducing specific mutations into a wild-type cell line, providing a controlled background. Examples include:

• • TET2 knockout cell lines: Used to study the role of TET2 in DNA methylation and hematopoiesis.
• • SF3B1 knock-in cell lines: Expressing the K700E mutation to investigate aberrant splicing.
• • TP53 knockout cell lines: To model loss-of-function and test therapeutic vulnerabilities.

These models are commercially available, sequence-verified, and can be custom-generated. They enable precise dissection of mutation effects and are invaluable for drug discovery.

Gene-edited cell lines are used to validate the functional impact of MDS-associated mutations. For example, TET2 knockout in TF-1 cells leads to increased self-renewal and altered differentiation, confirming its role as a tumor suppressor. Similarly, SF3B1 K700E knock-in models recapitulate aberrant splicing and erythroid defects. These models allow researchers to study gene function in a controlled genetic background.

Isogenic cell line pairs (wild-type vs. mutant) are powerful tools for drug screening. They enable identification of compounds that selectively target mutant cells, reducing off-target effects. For example, screening against SF3B1-mutant cells has identified splicing modulators as potential therapeutics. Additionally, resistance mechanisms can be studied by exposing cells to increasing drug concentrations and identifying secondary mutations.

CRISPR-based synthetic lethality screens using gene-edited cell lines can identify novel therapeutic targets. For instance, in TP53-mutant MDS cells, screening for genes whose knockdown is lethal can reveal vulnerabilities that can be exploited. This approach has identified PARP inhibitors as potential agents in TP53-mutant MDS. Gene-edited models also facilitate the discovery of biomarkers for diagnosis and prognosis.